4//SEC Filing
Mathew Aby J. 4
Accession 0001628280-25-014184
CIK 0000834365other
Filed
Mar 19, 8:00 PM ET
Accepted
Mar 20, 7:08 PM ET
Size
7.1 KB
Accession
0001628280-25-014184
Insider Transaction Report
Form 4
Mathew Aby J.
EVP & Chief Scientific Officer
Transactions
- Award
Common Stock
2025-03-18+22,919→ 283,520 total - Award
Common Stock
2025-03-18+36,645→ 320,165 total
Footnotes (2)
- [F1]The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation.
- [F2]The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 175% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
Documents
Issuer
BIOLIFE SOLUTIONS INC
CIK 0000834365
Entity typeother
Related Parties
1- filerCIK 0001556355
Filing Metadata
- Form type
- 4
- Filed
- Mar 19, 8:00 PM ET
- Accepted
- Mar 20, 7:08 PM ET
- Size
- 7.1 KB